Leaps by Bayer's head of healthcare venture investments, Lucio Iannone, is set to be managing director for diabetes-focused VC investor The T1D Fund.
Lucio Iannone is set to leave pharmaceutical and chemical group Bayer’s corporate venture capital arm for a managing director role at venture capital fund The T1D Fund.
Iannone will join T1D Fund in August following almost eight years at Leaps, four as US-based head of health venture investments at the unit. He made GCV’s Emerging Leaders list in 2023 and 2024.
His role at Leaps involved Iannone identifying, developing and managing the unit’s biotech ventures portfolio and leading the venture team in deals and due diligence.
T1D Fund focuses on cures for type 1 diabetes. Iannone will help drive its impact investment strategy in areas such as deal flow, investment approaches and portfolio company support.
Iannone originally joined Leaps in 2017 as senior director of venture investments following two years heading business development for genetic medicine developer
